Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9991970 | 0.97 | TSHR (0.39) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Hydrochloric Acid SCHEMBL28145155 | 0.95 | TSHR (0.37) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL12520312 | 0.78 | TSHR (0.38) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL18855422 | 0.77 | TSHR (0.36) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL16499846 | 0.72 | APLNR (0.32) | APLNR | |
| SCHEMBL4318930 | 0.72 | TSHR (0.46) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL18709642 | 0.70 | APLNR (0.33) | APLNR | |
| SCHEMBL1933726 | 0.70 | APLNR (0.31) | APLNR | |
| SCHEMBL28947688 | 0.70 | TSHR (0.44) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL28947686 | 0.70 | TSHR (0.44) | TSHRLMNACYP3A4GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TSHR 3292/4885LMNA 2521/4885CYP3A4 11/4885 |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TSHR 3292/4885LMNA 2521/4885CYP3A4 11/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | TSHR 3292/4885LMNA 2521/4885CYP3A4 11/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TSHR 3292/4885LMNA 2521/4885CYP3A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.